Safety and efficacy of the RTS,S/AS01E candidate malaria vaccine given with expanded-programme-on-immunisation vaccines: 19 month follow-up of a randomised, open-label, phase 2 trial

Kwaku Poku Asante; Salim Abdulla; Sélidji Todagbé Agnandji; John Lyimo; Johan Vekemans; Solange Soulanoudjingar; Ruth Owusu; Mwanajaa Shomari; Amanda Leach; Erik Jongert; Nahya Salim; José Francisco Fernandes; David Dosoo; Maria Chikawe; Saadou Issifou; Kingsley Osei-Kwakye; Marc Lievens; Maria Paricek; Tina Möller; Stephen Apanga; Grace Mwangoka; Marie‐Claude Dubois; Tigani Madi; Evans Kwara; Rose Minja; Aurore Bouyoukou Hounkpatin; Owusu Boahen; Kingsley Kayan; George Adjei; Daniel Chandramohan; Terrell Carter; Preeti Vansadia; Marla Sillman; Barbara Savarese; Christian Loucq; Didier Lapierre; Brian Greenwood; Joe Cohen; Peter G. Kremsner; Seth Owusu‐Agyei; Marcel Tanner; Bertrand Lell

doi:10.1016/s1473-3099(11)70100-1

Keywords

MedicineVaccinationAdverse effectMalaria vaccineMalariaMeasles vaccineMeaslesDiphtheriaPediatricsVaccination scheduleTetanusVaccine efficacyImmunizationPlasmodium falciparumInternal medicineVirologyImmunologyAntibody

Affiliated Institutions

Related Publications

Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial

Pedro M. Folegatti , Katie Ewer , Parvinder K. Aley +97 more

The pandemic of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) might be curtailed by vaccination. We assessed the safety, reactogenicity, and immunogenicity of a v...

2020 The Lancet 2590 citations

Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine in healthy adults aged 18–59 years: a randomised, double-blind, placebo-controlled, phase 1/2 clinical trial

Yanjun Zhang , Gang Zeng , Hongxing Pan +17 more

With the unprecedented morbidity and mortality associated with the COVID-19 pandemic, a vaccine against COVID-19 is urgently needed. We investigated CoronaVac (Sinovac Life Scie...

2020 The Lancet Infectious Diseases 1488 citations

Publication Info

Year: 2011
Type: article
Volume: 11
Issue: 10
Pages: 741-749
Citations: 134
Access: Closed

External Links

View on DOI.org

Social Impact

Altmetric

Safety and efficacy of the RTS,S/AS01E candidate malaria vaccine given with expanded-programme-on-immunisation vaccines: 19 month follow-up of a randomised, open-label, phase 2 trial

PlumX Metrics

Social media, news, blog, policy document mentions

Citation Metrics

134

OpenAlex

Cite This

APA Style

                            
                                
                                    Kwaku Poku Asante, 
                                
                                    Salim Abdulla, 
                                
                                    Sélidji Todagbé Agnandji
                                
                                et al.
                            
                            (2011). 
                            Safety and efficacy of the RTS,S/AS01E candidate malaria vaccine given with expanded-programme-on-immunisation vaccines: 19 month follow-up of a randomised, open-label, phase 2 trial. 
                            The Lancet Infectious Diseases
                            , 11
                            (10)
                            , 741-749.
                            https://doi.org/10.1016/s1473-3099(11)70100-1
                        

Identifiers

DOI: 10.1016/s1473-3099(11)70100-1